OBJECTIVES: The gold standard for the diagnosis of fat malabsorption, the 72-hour fat balance study, requires a 3-day collection to generate a coefficient of fat absorption (CFA). We hypothesized that a new test using behenic acid (behenate test) as a nonabsorbable lipid marker may provide a facile means to assess fat absorption. The study proposed to answer 2 questions: first, whether the behenate test correlated with the gold standard and, second, whether the CFA improved when taking pancreatic enzymes during meals instead of taking them before meals. PATIENTS AND METHODS: The study compared the behenate test with the gold standard in 15 patients with cystic fibrosis during 3 arms that require 3- to 4-day hospitalization: first, taking pancreatic enzymes before meals; second, taking it during meals; and third, without taking it. RESULTS: The mean CFA was 78.3% when pancreatic enzymes were taken during meals and 80.4% when these enzymes were taken before meals. Correlation between the CFA and the behenate test for collections during all 3 arms was r = 0.219 (P = 0.001). CONCLUSIONS: Timing of ingestion of pancreatic enzymes does not significantly alter the CFA. Although the CFA correlates with the behenate test, the correlation is not robust enough to justify replacement of the gold standard by this test. It is unclear whether the poor correlation between tests relates to intermeal variability in fat excretion or other factors; however, the behenate test may be suitable as a screening test for the detection of fat malabsorption.
OBJECTIVES: The gold standard for the diagnosis of fat malabsorption, the 72-hour fat balance study, requires a 3-day collection to generate a coefficient of fat absorption (CFA). We hypothesized that a new test using behenic acid (behenate test) as a nonabsorbable lipid marker may provide a facile means to assess fat absorption. The study proposed to answer 2 questions: first, whether the behenate test correlated with the gold standard and, second, whether the CFA improved when taking pancreatic enzymes during meals instead of taking them before meals. PATIENTS AND METHODS: The study compared the behenate test with the gold standard in 15 patients with cystic fibrosis during 3 arms that require 3- to 4-day hospitalization: first, taking pancreatic enzymes before meals; second, taking it during meals; and third, without taking it. RESULTS: The mean CFA was 78.3% when pancreatic enzymes were taken during meals and 80.4% when these enzymes were taken before meals. Correlation between the CFA and the behenate test for collections during all 3 arms was r = 0.219 (P = 0.001). CONCLUSIONS: Timing of ingestion of pancreatic enzymes does not significantly alter the CFA. Although the CFA correlates with the behenate test, the correlation is not robust enough to justify replacement of the gold standard by this test. It is unclear whether the poor correlation between tests relates to intermeal variability in fat excretion or other factors; however, the behenate test may be suitable as a screening test for the detection of fat malabsorption.
Authors: Mary H Wagner; Ellen K Bowser; James M Sherman; Mary Pat Francisco; Douglas Theriaque; Donald A Novak Journal: J Pediatr Gastroenterol Nutr Date: 2002-08 Impact factor: 2.839
Authors: A Van den Neucker; N Pestel; T M Tran; P P Forget; H J Veeze; J Bouquet; M Sinaasappel Journal: Acta Paediatr Date: 1997-05 Impact factor: 2.299
Authors: L Benini; L A Scuro; E Menini; C Manfrini; I Vantini; B Vaona; G Brocco; G Talamini; G Cavallini Journal: Digestion Date: 1984 Impact factor: 3.216
Authors: Maria R Mascarenhas; John Mondick; Jeffrey S Barrett; Martha Wilson; Virginia A Stallings; Joan I Schall Journal: J Clin Pharmacol Date: 2015-03-23 Impact factor: 3.126
Authors: Sudipta Dhar Chowdhury; Reuben Thomas Kurien; Anup Ramachandran; Anjilivelil Joseph Joseph; Ebby George Simon; Amit Kumar Dutta; Deepu David; Bharath Kumar C; Prassana Samuel; K A Balasubramaniam Journal: Indian J Gastroenterol Date: 2016-11-23
Authors: Joaquim Calvo-Lerma; Maria Roca; Mieke Boon; Carla Colombo; Barbara de Koning; Victoria Fornés-Ferrer; Etna Masip; Maria Garriga; Anna Bulfamante; Andrea Asensio-Grau; Ana Andrés; Kris de Boeck; Jessie Hulst; Carmen Ribes-Koninckx Journal: Pediatr Res Date: 2020-04-04 Impact factor: 3.756
Authors: Joaquim Calvo-Lerma; Jessie Hulst; Mieke Boon; Carla Colombo; Etna Masip; Mar Ruperto; Victoria Fornés-Ferrer; Els van der Wiel; Ine Claes; Maria Garriga; Maria Roca; Paula Crespo-Escobar; Anna Bulfamante; Sandra Woodcock; Sandra Martínez-Barona; Ana Andrés; Kris de Boeck; Carmen Ribes-Koninckx Journal: PLoS One Date: 2019-03-12 Impact factor: 3.240